Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
NX-5948 is being studied in a Phase 1 trial for adults with relapsed/refractory B-cell malignancies; the study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: SynKIR-310 for Relapsed/Refractory B-NHL [Phase 1]
Phase 1 trial update for SynKIR-310 in relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma [Phase 2]
This is a Phase 2 clinical trial update evaluating a three-drug combination of obinutuzumab, ibrutinib, and venetoclax for previously untrea…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma [Phase 3]
A Phase 3 trial evaluating subcutaneous epcoritamab plus intravenous rituximab and oral lenalidomide (R2) in adults with previously untreate…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma [Phase 3]
A Phase 3 clinical trial update describes a study evaluating whether odronextamab combined with lenalidomide is safe and more effective than…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma [Phase 1]
A Phase 1 trial is evaluating the addition of the immunotherapy atezolizumab to a Rituximab-Gemcitabine-Oxaliplatin regimen for relapsed/ref…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Long-term Extension Study of PCI-32765 (Ibrutinib) [Phase 3]
Phase 3 long-term extension study of ibrutinib (PCI-32765) in chronic lymphocytic leukemia/small lymphocytic lymphoma and other B-cell malig…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma [Phase 1]
This clinical trial update describes a Phase 1 study evaluating rituximab, lenalidomide, and ibrutinib in patients with previously untreated…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma [Phase 2]
Phase 2 clinical trial evaluating obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy for relapsed or refract…
-
EMA withdrawal · 2026-04-09EMA Withdrawn: Copiktra (duvelisib) — Secura Bio Limited
The European Medicines Agency has withdrawn the marketing authorization for Copiktra (duvelisib) from Secura Bio Limited; the drug for chron…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
This document provides a long-term follow-up update on allogeneic gamma delta CAR T cell therapy. The trial covers several B-cell lymphoma i…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) [Phase 1, Phase 2]
This is a Phase 1/2 clinical study of MK-1045 for non-Hodgkin lymphoma, including follicular lymphoma and diffuse large B-cell lymphoma, wit…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma [Phase 1, Phase 2]
Genmab-sponsored first-in-human trial in relapsed/refractory B-cell lymphomas spans Phase 1/2 and is currently active/not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T [Phase 1]
This clinical trial update reports long-term follow-up results from a Phase 1 study of CLBR001 CAR-T cells in relapsed/refractory B-cell lym…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) [Phase 1, Phase 2]
Clinical trial update announcing a Phase 1/2 study of epcoritamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lympho…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) [Phase 1, Phase 2]
Clinical trial update on a phase 1/2 study evaluating safety and efficacy of epcoritamab combinations in adults with diffuse large B-cell ly…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma [Phase 2]
This clinical trial update reports a Phase 2 study of obinutuzumab in combination with CC-99282 for previously untreated high tumor burden f…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma [Phase 2]
Clinical trial update on a Phase II study of tazemetostat in combination with mosunetuzumab for untreated follicular lymphoma; the trial is …
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial of tazemetostat plus venetoclax for relapsed/refractory non-Hodgkin lymphoma has been terminated, including diffuse l…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma [Phase 1]
Phase 1 study update for VAY736 in non-Hodgkin lymphoma shows the trial status as terminated, evaluating VAY736 alone and in combination wit…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma [Phase 2]
Phase 2 trial comparing ZR2 versus R2 regimen in newly diagnosed follicular lymphoma; currently not yet recruiting.
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies [Phase 1, Phase 2]
Phase 1/2 trial update for SHB-02-CD19, a novel CD19-directed CAR-T therapy, in CD19-expressing B-cell malignancies; recruitment not yet sta…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) [Phase 1, Phase 2]
A Phase 1/2 clinical trial of SENTRY-CD19, a CD19-targeted gene therapy, in multiple CD19-positive hematologic malignancies is currently rec…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) [Phase 2, Phase 3]
Clinical trial update for NexCAR19 (Talikabtagene autoleucel), a CAR-T therapy studied in relapsed/refractory B-cell malignancies; the Phase…
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial assessed first-line therapy combining bortezomib, chemotherapy, and rituximab in patients with stage III or IV follicular ly…